Endo to present nine XIAFLEX studies in Peyronie’s disease at SMSNA Annual Meeting 2025
Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced that nine presentations related to Peyronie’s disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, injection 0.9 mg) will be shared… read more.
